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Abstract
The study aimed to evaluate neopterin levels in cerebro-spinal
fluid (CSF) as a marker of disease activation and progression
of multiple sclerosis (MS).
Neopterin, a substance known to be released from macroph-
ages and monocytes at increased rates in cellular immune re-
actions, was investigated by radio- immunoassay, in the CSF
of 19 patients with MS during exacerbations of the disease, in
34 patients with other neurological diseases (OND) and in 20
normal subjects used as controls. Posers criteria were used
for the diagnosis of MS.
Although elevated neopterin levels in the CSF of patients with
MS during exacerbations have been reported by other investiga-
tors, we found such elevation in only 4 out of 19 patients with MS
(21%), in 5 out of 34 patients with OND (14.7%), and in none of
the control group. Students t-test was used for statistical analy-
sis. There was no significant difference in the CSF values of the
MS patients, the patients with OND (p > 0.05) or the controls.
These results indicate that neopterin levels in CSF may not be
considered a marker of disease activity in MS.
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Introduction
Neopterin is a pyrazino-2,3 d-pyrimidine derivative formed
from quanosintriphosphate (GTP) in the synthesis pathway of
biopterin, which acts as a cofactor in neurotransmitter synthesis
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 i.e., in hydroxylation of phenylalanine, tyrosine and tryptophan
[1, 2]. It is released from monocytes and macrophages after stim-
ulation in vitro by gamma interferon (gamma IFN) from activated
T cells [3]. Release of neopterin from peripheral blood mononu-
clear cells in vitro was shown to be induced through activation of
T cells stimulated by alloantigens or by virally modified autolo-
gous cells [4].
Multiple sclerosis (MS) is a demyelinating disease of the
central nervous system (CNS). Although the etiology of MS is
still unclear, pathology studies have indicated that infiltrating
cells are composed mainly of activated T cells and monocytes-
macrophages. Elevated neopterin levels in the CSF of patients
with MS during exacerbations have been reported [5, 6], while
others did not find differences in CSF levels of neopterin in pa-
tients with MS, those with other neurological diseases and
healthy controls [7]. Increased neopterin excretion in serum and
urine has also been described in patients with viral infections
[8, 9], rheumatoid arthritis, systemic lupus erythematosus, co-
eliac disease [10], malaria [11] and certain tumours [8]. Neop-
terin has also been used as a biochemical marker of cellular
immune response and T-cell activation [1, 11] and to follow the
clinical course during different therapeutic trials  e.g., with
interleukin-2 in patients with acquired immune deficiency syn-
drome (AIDS) [12].
The purpose of this study was to determine if neopterin levels
are increased in the CSF and if neopterin is a valuable marker of
acute cellular immune response and should represent an objec-
tive way to monitor disease activity in MS.
Material and methods
Patients
Multiple sclerosis. Nineteen patients (11 female, 8 male,
aged 25 to 60 years; mean age 40.4 years) were clinically diag-
nosed with MS as defined by the criteria of Poser, et al. [13] None
of the patients was treated with immunotherapeutic or other relat-
ed drugs during the study.
Control Subjects with OND. Fifty-four patients (20 female,
34 male, aged 21 to 81 years; mean age 53.7 years) with OND
were studied. Of these patients 9 were with cerebral infarctions,
4 with Guillain-Barre syndrome, 4 with polyneuropathy, 8 with de-
mentia, 4 with paraparesis, 2 with Parkinsons disease, 2 with
meningioma and 1 with acoustic neurinoma.
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Healthy Control Subjects. Twenty individuals (8 female,
12 male, aged 29 to 53 years; mean age 45.7 years) with tension
headache or psychoneurotic disorders constituted a control group
for establishing the upper reference level of neopterin concentra-
tions in CSF.
CSF samples were taken between 10:00 and 12:00 hours.
15 ml of CSF was obtained by lumbar puncture. Cells, protein
and glucose levels in CSF were measured. The remaining CSF
was stored at 20° C in a refrigerator where it was protected against
light until use (in a Symbol 176\f Symbol C). Oligoclonal bands
in CSF and serum were determined by agarose gel electrophore-
sis. Neopterin in CSF was measured with a standard radio immu-
noassay (RIA) within 6 months after sampling.
The upper reference limit of neopterin in CSF was 2.5 ng/ml.
Total and differential counts of CSF cells were also performed. Deter-
minations of lgG and albumin were carried out on unconcentrated
CSF. Oligoclonal bands in serum and CSF were tested by agarose
gel electrophoresis. Before electrophoresis, CSF was concentrated
80100 times using an Amicron B10 macrosolute concentrator.
Statistical analysis
Mean neopterin levels in CSF among patients with MS and
OND, and healthy control subjects were compared by the Stu-
dents t-test and regression analysis.
Results
CSF neopterin levels of 2.5 ng/mL or higher were found in 4
(21%) of 19 patients with MS, in 5 (14.7%) of 34 patients with OND
and in none of 20 healthy control subjects. The patients with OND
who had an elevated CSF neopterin level included 1 of 4 with para-
paresis, 1 of 4 with polyneuropathy, 1 of 4 with Guillain-Barre syn-
drome, 1 of 8 with dementia (vascular dementia) and 1 of 9 with
stroke.
The mean CSF neopterin levels for all MS patients did not
significantly differ from those of the controls or of the patients with
OND (p < 0.05).
Very high or high neopterin levels were found in one patient
with paraparesis (14 ng/ml), in one with cervical disc (20 ng/ml),
in one with neuropathy (12 ng/ml), in one who had a history of
vascular dementia and in one with stroke (3 ng/ml). Very high
neopterin levels were also found in MS patients (20, 20.8, and
8.4 ng/ml).
CSF neopterin levels, protein, cells and glucose in MS pa-
tients are shown in Table 1. Mean values and standard deviation
of all neopterin values in patients and controls are shown in Table 2.
Normal neopterin values are up to 2.5 ng/ml.
Discussion
It is known that symptoms and signs will only partly reflect the
abnormal CNS test in MS patients. This has been demonstrated
when autopsy materials are tested [14, 15] and also when clinical
symptoms and signs are correlated to findings from magnetic res-
onance imaging (MRI) [16, 17]. Jacobs et al. (1986) showed that
75% of lesions detected on MRI were clinically silent and only 5%
were definitely related to symptoms and signs.
Elevated serum neopterin levels occur in several acute and
chronic infections including HIV, and haematologic malignancies
and also during graft rejection [18]. Serum neopterin levels in pa-
tients with OND, peripheral neuropathies or MS, who were in clin-
ically stable condition at the time of testing, were not significantly
different from levels in healthy controls. However, mean neopterin
levels in patients with OND were significantly higher (p < 0.05)
than levels in patients with MS [7].
In other studies, CSF levels of neopterin were higher in patients
with MS during exacerbation [5, 19, 20] and in the relapsing-remit-
ting type of the disease [21]. The significant CSF increase in neop-
terin described in some references was not reflected in serum [19,
22], suggesting possible intrathecal production of neopterin.
In this study we found no statistical difference in neopterin
CSF levels among patients with MS and OND, and the controls. In
addition, we found very high neopterin levels in 5 patients with
OND: one with paraparesis, one with polyneuropathy, one with
Guillain-Barre syndrome, one with vascular dementia and one with
stroke. We found no explanation for this finding although it could
reflect non-specific immune activation due to damage in the cen-
tral nervous system or in the peripheral nerves.
Conclusion
In conclusion, it seems that determination of neopterin CSF lev-
els cannot be used as a marker of disease activity in MS patients.
Table 1. CSF neopterin levels, protein, cells and glucose in MS
patients
Patients Age Neopterin Protein Cells Glucose
1. AM 25 20 10 0 66
2. DP 30 0.2 30 1 63
3. ZA 30 0.7 18 5 79
4. TP 41 8.4 18 1 66
5. IA 29 0.34 18 1 66
6. KM 33 0.6 77 0 88
7. BE 35 0.4 15 3 75
8. SK 60 8 18 60 71
9. SM 32 0.1 45 15 94
10. FA 60 0.18 20 4 65
11. AA 39 20 10 0 66
12. M 35 0.34 18 3 71
13. SA 38 5 22 0 70
14. PM 28 0.54 28 1 78
15. SG 35 0.6 70 1 55
16. FS 40 0.3 19 0 67
17. PP 38 0.3 25 3 75
18. ED 25 0.2 15 0 73
19. D 32 0.2 28 0 98
Table 2. Mean values and standard deviation of all neopterin levels
in patients and controls
Groups Neopterin [ng/ml]
MS 1.38 – 3.38
Controls 1.85 – 4.04
OND 0.34 – 0.38
p = 0.13
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